“At the end of 2030, there will be more mRNA-based mAbs in clinical trials than those of protein-based mAbs.”

Monoclonal antibodies (mAbs) industry has a global market over $100 billion, and they are currently manufactured and delivered in protein format. The recent success of mRNA covid-19 vaccines from Pfizer/BioNTech and Moderna highlights the rapid growth of mRNA technology. mRNA that encodes mAb of interest will emerge as an attractive alternative to replace protein-based mAbs, offering a new kind of safer and cheaper molecular therapeutics. At the end of 2030, there will be at least one mRNA-based mAb that has been approved by a government regulation body, and there will be more mRNA-based mAbs in clinical trials than those of protein-based mAbs.